La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kingworld Medicines Group Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Kingworld Medicines Group.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Healthcare crescita degli utili	16.2%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338

May 31

Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely

May 22

Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings

Apr 29

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Apr 23

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Mar 22

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Nov 30

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Aug 17

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

May 30

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

May 11

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Apr 03

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Feb 07

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Oct 07

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Jul 05

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Apr 27

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Aug 17

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Apr 24

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Mar 29

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Mar 08

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Feb 15

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Jan 25

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Kingworld Medicines Group non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

SEHK:1110 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2023	1,079	38	-63	42	N/A
9/30/2023	1,085	37	-15	110	N/A
6/30/2023	1,091	36	34	177	N/A
3/31/2023	1,024	29	64	182	N/A
12/31/2022	958	23	93	187	N/A
9/30/2022	905	29	66	159	N/A
6/30/2022	852	35	40	131	N/A
3/31/2022	850	33	31	106	N/A
12/31/2021	847	30	23	81	N/A
9/30/2021	858	26	76	111	N/A
6/30/2021	868	21	129	141	N/A
3/31/2021	807	17	121	132	N/A
12/31/2020	745	12	114	124	N/A
9/30/2020	749	16	90	99	N/A
6/30/2020	752	20	66	74	N/A
3/31/2020	865	32	95	103	N/A
12/31/2019	978	43	124	133	N/A
9/30/2019	1,010	45	79	88	N/A
6/30/2019	1,041	46	34	44	N/A
3/31/2019	1,060	44	42	53	N/A
12/31/2018	1,079	41	51	62	N/A
9/30/2018	1,079	49	60	85	N/A
6/30/2018	1,079	56	70	108	N/A
3/31/2018	1,055	54	51	90	N/A
12/31/2017	1,031	51	32	72	N/A
9/30/2017	1,088	50	N/A	58	N/A
6/30/2017	1,145	49	N/A	43	N/A
3/31/2017	1,099	48	N/A	20	N/A
12/31/2016	1,054	47	N/A	-4	N/A
9/30/2016	909	41	N/A	20	N/A
6/30/2016	764	35	N/A	44	N/A
3/31/2016	739	34	N/A	74	N/A
12/31/2015	714	32	N/A	103	N/A
9/30/2015	711	34	N/A	56	N/A
6/30/2015	708	36	N/A	10	N/A
3/31/2015	684	37	N/A	2	N/A
12/31/2014	660	38	N/A	-5	N/A
9/30/2014	640	43	N/A	-21	N/A
6/30/2014	619	48	N/A	-38	N/A
3/31/2014	587	48	N/A	-44	N/A
12/31/2013	555	47	N/A	-50	N/A
9/30/2013	571	47	N/A	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 1110 è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 1110 cresceranno più velocemente del mercato Hong Kong

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 1110 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di 1110 cresceranno più rapidamente del mercato Hong Kong.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di 1110 cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 1110 è previsto essere elevato tra 3 anni

Kingworld Medicines Group Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Kingworld Medicines Group Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2020

Recent updates

Kingworld Medicines Group Limited to Report First Half, 2024 Results on Aug 28, 2024

Now 23% undervalued

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338

Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Now 22% undervalued

Upcoming dividend of HK$0.034 per share

Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely

Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings

Full year 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.037 in FY 2022)

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Kingworld Medicines Group Limited, Annual General Meeting, May 29, 2024

Full year 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.037 in FY 2022)

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Kingworld Medicines Group Limited to Report Fiscal Year 2023 Final Results on Mar 26, 2024

Now 29% overvalued

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.04 in 1H 2022)

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Kingworld Medicines Group Limited to Report First Half, 2023 Results on Aug 28, 2023

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 3.0% yield

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Full year 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.05 in FY 2021)

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Investor sentiment improved over the past week

Insufficient new directors

Now 22% undervalued after recent price drop

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Now 24% undervalued

First half 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.032 in 1H 2021)

Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Co-Founder recently bought HK$297k worth of stock

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Kingworld Medicines Group Limited Announces Final Cash Dividend for the Financial Year Ended 31 December 2021, Payable on 30 June 2022

Upcoming dividend of HK$0.024 per share

Full year 2021 earnings released: EPS: CN¥0.05 (vs CN¥0.019 in FY 2020)

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Less than half of directors are independent

Co-Founder recently bought HK$280k worth of stock

Kingworld Medicines Group Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.05 (vs CN¥0.019 in FY 2020)

Kingworld Medicines Group Limited, Annual General Meeting, May 27, 2022

Kingworld Medicines Group Limited, Annual General Meeting, May 27, 2022

First half 2021 earnings released: EPS CN¥0.032 (vs CN¥0.016 in 1H 2020)

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group Limited Declares Final Dividend for the Year Ended December 31, 2020

Full year 2020 earnings released: EPS CN¥0.019 (vs CN¥0.07 in FY 2019)

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Full year 2020 earnings released: EPS CN¥0.019 (vs CN¥0.07 in FY 2019)

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2020

Kingworld Medicines Group Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

New 90-day low: HK$0.67

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

New 90-day low: HK$0.73

Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Kingworld Medicines Group Limited Enters Distribution Agreement with Shenzhen Ausa Pharmaceutical Co., Ltd

Executive Director recently sold HK$1.3m worth of stock

New 90-day high: HK$0.80

First half earnings released

New 90-day low - HK$0.71

First half earnings released

Kingworld Medicines Group Limited to Report First Half, 2020 Results on Aug 26, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione